[1]
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. The Cochrane database of systematic reviews. 2017 Jan 20:1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5. Epub 2017 Jan 20
[PubMed PMID: 28107561]
Level 1 (high-level) evidence
[2]
. Beta Adrenergic Blocking Agents. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():
[PubMed PMID: 31643457]
[3]
Paulison B, Léos CL. Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature. Cardiovascular toxicology. 2010 Dec:10(4):306-10. doi: 10.1007/s12012-010-9088-5. Epub
[PubMed PMID: 20865460]
Level 3 (low-level) evidence
[4]
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun:71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13
[PubMed PMID: 29133356]
Level 1 (high-level) evidence
[5]
Wang SJ, Sander GE. Nebivolol/valsartan combination for the treatment of hypertension: a review. Future cardiology. 2021 Jul:17(4):573-583. doi: 10.2217/fca-2020-0079. Epub 2020 Oct 16
[PubMed PMID: 33064027]
[6]
Authors/Task Force Members:, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2022 Jan:24(1):4-131. doi: 10.1002/ejhf.2333. Epub
[PubMed PMID: 35083827]
[7]
Marchini F, Pompei G, D'Aniello E, Marrone A, Caglioni S, Biscaglia S, Campo G, Tebaldi M. Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic Review. Cardiovascular drugs and therapy. 2024 Feb:38(1):151-161. doi: 10.1007/s10557-022-07351-x. Epub 2022 Jun 9
[PubMed PMID: 35678926]
Level 1 (high-level) evidence
[8]
Cannata F, Stefanini G, Carlo-Stella C, Chiarito M, Figliozzi S, Novelli L, Lisi C, Bombace S, Panico C, Cosco F, Corrado F, Masci G, Mazza R, Ricci F, Monti L, Ferrante G, Santoro A, Francone M, da Costa BR, Jüni P, Condorelli G. Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design. Journal of cardiovascular medicine (Hagerstown, Md.). 2023 Jul 1:24(7):469-474. doi: 10.2459/JCM.0000000000001491. Epub
[PubMed PMID: 37285278]
[9]
Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, Kalay N, Dikilitas M, Yarlioglues M, Karaca H, Berk V, Ardic I, Ergin A, Lam YY. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. International journal of cardiology. 2013 Sep 1:167(5):2306-10. doi: 10.1016/j.ijcard.2012.06.023. Epub 2012 Jun 22
[PubMed PMID: 22727976]
Level 1 (high-level) evidence
[10]
Mir A, Badi Y, Bugazia S, Nourelden AZ, Fathallah AH, Ragab KM, Alsillak M, Elsayed SM, Hagrass AI, Bawek S, Kalot M, Brumberger ZL. Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis. Cardio-oncology (London, England). 2023 Feb 18:9(1):10. doi: 10.1186/s40959-023-00159-0. Epub 2023 Feb 18
[PubMed PMID: 36804940]
Level 1 (high-level) evidence
[11]
Weiss R. Nebivolol: novel beta-blocker with nitric oxide-induced vasodilation. Future cardiology. 2006 Jan:2(1):9-16. doi: 10.2217/14796678.2.1.9. Epub
[PubMed PMID: 19804126]
[12]
Ågesen FN, Weeke PE, Tfelt-Hansen P, Tfelt-Hansen J, for ESCAPE‐NET. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacology research & perspectives. 2019 Aug:7(4):e00496. doi: 10.1002/prp2.496. Epub 2019 Jul 12
[PubMed PMID: 31338197]
Level 3 (low-level) evidence
[13]
Olawi N, Krüger M, Grimm D, Infanger M, Wehland M. Nebivolol in the treatment of arterial hypertension. Basic & clinical pharmacology & toxicology. 2019 Sep:125(3):189-201. doi: 10.1111/bcpt.13248. Epub 2019 Jul 4
[PubMed PMID: 31066991]
[14]
McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs. 1999 Apr:57(4):633-51
[PubMed PMID: 10235696]
[15]
Fongemie J, Felix-Getzik E. A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs. 2015 Aug:75(12):1349-71. doi: 10.1007/s40265-015-0435-5. Epub
[PubMed PMID: 26177892]
[16]
AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease. Cardiovascular drugs and therapy. 2022 Oct:36(5):959-971. doi: 10.1007/s10557-021-07205-y. Epub 2021 Jun 9
[PubMed PMID: 34106365]
[17]
Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC. Heart failure. 2015 Aug:3(8):647-53. doi: 10.1016/j.jchf.2015.03.008. Epub
[PubMed PMID: 26251094]
Level 1 (high-level) evidence
[18]
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European heart journal. 2018 Sep 7:39(34):3165-3241. doi: 10.1093/eurheartj/ehy340. Epub
[PubMed PMID: 30165544]
[20]
. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstetrics and gynecology. 2020 Jun:135(6):e237-e260. doi: 10.1097/AOG.0000000000003891. Epub
[PubMed PMID: 32443079]
[21]
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European heart journal. 2005 Feb:26(3):215-25
[PubMed PMID: 15642700]
Level 1 (high-level) evidence
[22]
Cicero AFG, Kuwabara M, Borghi C. A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension. Drugs. 2018 Nov:78(17):1783-1790. doi: 10.1007/s40265-018-0999-y. Epub
[PubMed PMID: 30426333]
[24]
Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacological research. 1998 Dec:38(6):419-31
[PubMed PMID: 9990650]
[25]
Lou IX, Chen J, Ali K, Chen Q. Relationship Between Hypertension, Antihypertensive Drugs and Sexual Dysfunction in Men and Women: A Literature Review. Vascular health and risk management. 2023:19():691-705. doi: 10.2147/VHRM.S439334. Epub 2023 Nov 3
[PubMed PMID: 37941540]
[26]
Awad VM, Sakhamuru S, Kambampati S, Wasim S, Malik BH. Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level. Cureus. 2020 Jul 2:12(7):e8964. doi: 10.7759/cureus.8964. Epub 2020 Jul 2
[PubMed PMID: 32766006]
[27]
Saedder EA, Thomsen AH, Hasselstrøm JB, Jornil JR. Heart insufficiency after combination of verapamil and metoprolol: A fatal case report and literature review. Clinical case reports. 2019 Nov:7(11):2042-2048. doi: 10.1002/ccr3.2393. Epub 2019 Sep 19
[PubMed PMID: 31788248]
Level 3 (low-level) evidence
[28]
Ong HT, Ong LM, Kow FP. Beta-blockers for heart failure: an evidence based review answering practical therapeutic questions. The Medical journal of Malaysia. 2012 Feb:67(1):7-11
[PubMed PMID: 22582541]
[29]
Pessina AC. Metabolic effects and safety profile of nebivolol. Journal of cardiovascular pharmacology. 2001 Dec:38 Suppl 3():S33-5
[PubMed PMID: 11811391]
[30]
. [Heart and lung disease. Are beta blockers allowed in asthma?]. MMW Fortschritte der Medizin. 2001 May 24:143(21):58
[PubMed PMID: 11420835]
[31]
Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clinical therapeutics. 2009 Mar:31(3):447-62. doi: 10.1016/j.clinthera.2009.03.007. Epub
[PubMed PMID: 19393838]
[32]
Zaritsky AL, Horowitz M, Chernow B. Glucagon antagonism of calcium channel blocker-induced myocardial dysfunction. Critical care medicine. 1988 Mar:16(3):246-51
[PubMed PMID: 3277781]
[33]
Heinroth KM, Kuhn C, Walper R, Busch I, Winkler M, Prondzinsky R. [Acute beta 1-selective beta-receptor blocker nebivolol poisoning in attempted suicide]. Deutsche medizinische Wochenschrift (1946). 1999 Oct 22:124(42):1230-4
[PubMed PMID: 10572531]
[34]
Murakami Y, Kaneko S, Yokoyama H, Ishizaki H, Sekino M, Murata H, Hara T. Successful treatment of severe adrenaline-resistant anaphylactic shock with glucagon in a patient taking a beta-blocker: a case report. JA clinical reports. 2021 Dec 15:7(1):86. doi: 10.1186/s40981-021-00490-4. Epub 2021 Dec 15
[PubMed PMID: 34907487]
Level 3 (low-level) evidence
[35]
Bouhanick B, Blacher J, Huyghe E, Colson MH, Boivin JM, Mounier-Vehier C, Denolle T, Fauvel JP. [Sexual dysfunction and antihypertensive treatment: Involvement of the different therapeutic classes and what to do about the treatment of hypertension]. Presse medicale (Paris, France : 1983). 2019 Nov:48(11 Pt 1):1222-1228. doi: 10.1016/j.lpm.2019.05.029. Epub 2019 Jul 11
[PubMed PMID: 31303372]
[36]
King AM, Danagoulian S, Lynch M, Menke N, Mu Y, Saul M, Abesamis M, Pizon AF. The Effect of a Medical Toxicology Inpatient Service in an Academic Tertiary Care Referral Center. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2019 Jan:15(1):12-21. doi: 10.1007/s13181-018-0684-2. Epub 2018 Oct 23
[PubMed PMID: 30353414]
[37]
Carter BL, Rogers M, Daly J, Zheng S, James PA. The potency of team-based care interventions for hypertension: a meta-analysis. Archives of internal medicine. 2009 Oct 26:169(19):1748-55. doi: 10.1001/archinternmed.2009.316. Epub
[PubMed PMID: 19858431]
Level 1 (high-level) evidence
[38]
Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ (Clinical research ed.). 2010 Aug 23:341():c3995. doi: 10.1136/bmj.c3995. Epub 2010 Aug 23
[PubMed PMID: 20732968]
Level 1 (high-level) evidence
[39]
Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffé P, Burnier M, Burnand B, Paradis G. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. Journal of the American Heart Association. 2014 Apr 10:3(2):e000718. doi: 10.1161/JAHA.113.000718. Epub 2014 Apr 10
[PubMed PMID: 24721801]
Level 1 (high-level) evidence